Cogent Biosciences (COGT) Other Accumulated Expenses (2017 - 2026)

Cogent Biosciences (COGT) has reported Other Accumulated Expenses for 9 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 281.4% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 281.4% YoY), while the FY2025 annual figure was $6.7 million, up 1708.31% from the prior year.
• Other Accumulated Expenses declined to $1.8 million in Q1 2026 per COGT's latest filing, from $6.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $6.7 million in Q4 2025 and bottomed at $252000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $496000.0 in 2023.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 68.23% — and 2025, when it jumped 1708.31%.
• Cogent Biosciences' Other Accumulated Expenses stood at $404000.0 in 2022, then advanced by 9.16% to $441000.0 in 2023, then retreated by 15.42% to $373000.0 in 2024, then surged by 1708.31% to $6.7 million in 2025, then slumped by 72.63% to $1.8 million in 2026.
• Business Quant data shows COGT's Other Accumulated Expenses at $1.8 million in Q1 2026, $6.7 million in Q4 2025, and $1.3 million in Q3 2025.